BSE filing, BSE: 540468. Summary written from the filing by ALFA Finder's alert engine.
More from Kms Medisurgi Ltd
All →KMS Medisurgi H2 FY26 Results: Net Profit ₹0 Cr
KMS Medisurgi Ltd reported revenue from operations of ₹5.6 Cr (-8.2% YoY) and net profit of ₹0 Cr for H2 FY26.
- Key figure
- Net profit ₹0 Cr
Kms Medisurgi Financial Results
KMS Medisurgi Limited reported audited standalone financial results for the year ended March 31, 2026. The results include a qualified auditor's opinion regarding stock records and employee benefits.
Kms Medisurgi Board Meeting Date
KMS Medisurgi scheduled a board meeting for May 30, 2026, to approve annual audited financial results. Trading window remains closed until 48 hours post-announcement.
Kms Medisurgi Other Announcement
KMS Medisurgi Limited submitted a non-applicability declaration regarding corporate governance reports for the year ended March 31, 2026. As an SME-listed entity, the company is exempt from these specific SEBI LODR disclosure requirements under Regulation 15(2).
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.